TuHURA Biosciences (HURA) Expected to Announce Earnings on Wednesday

TuHURA Biosciences (NASDAQ:HURA) is projected to release its earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter.

TuHURA Biosciences Stock Up 0.9 %

Shares of TuHURA Biosciences stock opened at $3.33 on Monday. The company has a fifty day moving average price of $4.37. TuHURA Biosciences has a fifty-two week low of $2.84 and a fifty-two week high of $14.60.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HURA shares. Maxim Group started coverage on TuHURA Biosciences in a report on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price objective for the company. RODMAN&RENSHAW upgraded TuHURA Biosciences to a “strong-buy” rating in a report on Thursday, December 19th. Finally, Rodman & Renshaw started coverage on TuHURA Biosciences in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price objective for the company.

Institutional Investors Weigh In On TuHURA Biosciences

An institutional investor recently bought a new position in TuHURA Biosciences stock. Bank of America Corp DE bought a new position in shares of TuHURA Biosciences (NASDAQ:HURA) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 14,314 shares of the company’s stock, valued at approximately $59,000. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.